These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9435165)

  • 1. Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.
    Zamboni WC; Houghton PJ; Johnson RK; Hulstein JL; Crom WR; Cheshire PJ; Hanna SK; Richmond LB; Luo X; Stewart CF
    J Pharmacol Exp Ther; 1998 Jan; 284(1):89-94. PubMed ID: 9435165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Involvement of rat and human organic anion transporter 3 in the renal tubular secretion of topotecan [(S)-9-dimethylaminomethyl-10-hydroxy-camptothecin hydrochloride].
    Matsumoto S; Yoshida K; Ishiguro N; Maeda T; Tamai I
    J Pharmacol Exp Ther; 2007 Sep; 322(3):1246-52. PubMed ID: 17556638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.
    Grochow LB; Rowinsky EK; Johnson R; Ludeman S; Kaufmann SH; McCabe FL; Smith BR; Hurowitz L; DeLisa A; Donehower RC
    Drug Metab Dispos; 1992; 20(5):706-13. PubMed ID: 1358575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of probenecid on the distribution and elimination of ciprofloxacin in humans.
    Jaehde U; Sörgel F; Reiter A; Sigl G; Naber KG; Schunack W
    Clin Pharmacol Ther; 1995 Nov; 58(5):532-41. PubMed ID: 7586947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No effect of probenecid on the renal excretion mechanism of a new carbapenem, DA-1131, in dogs.
    Kim SH; Kim WB; Lee MG
    Res Commun Mol Pathol Pharmacol; 1998 Jul; 101(1):85-92. PubMed ID: 9755846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal tubular secretion and reabsorption as factors in ochratoxicosis: effects of probenecid on nephrotoxicity.
    Stein AF; Phillips TD; Kubena LF; Harvey RB
    J Toxicol Environ Health; 1985; 16(3-4):593-605. PubMed ID: 4087321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of cimetidine and probenecid on pilsicainide renal clearance in humans.
    Shiga T; Hashiguchi M; Urae A; Kasanuki H; Rikihisa T
    Clin Pharmacol Ther; 2000 Mar; 67(3):222-8. PubMed ID: 10741624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergy of topotecan in combination with vincristine for treatment of pediatric solid tumor xenografts.
    Thompson J; George EO; Poquette CA; Cheshire PJ; Richmond LB; de Graaf SS; Ma M; Stewart CF; Houghton PJ
    Clin Cancer Res; 1999 Nov; 5(11):3617-31. PubMed ID: 10589779
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice.
    Shen H; Ocheltree SM; Hu Y; Keep RF; Smith DE
    Drug Metab Dispos; 2007 Jul; 35(7):1209-16. PubMed ID: 17452417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction.
    Herrington JD; Figueroa JA; Kirstein MN; Zamboni WC; Stewart CF
    Cancer Chemother Pharmacol; 2001; 47(1):89-93. PubMed ID: 11221968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Probenecid, but not cystic fibrosis, alters the total and renal clearance of fexofenadine.
    Liu S; Beringer PM; Hidayat L; Rao AP; Louie S; Burckart GJ; Shapiro B
    J Clin Pharmacol; 2008 Aug; 48(8):957-65. PubMed ID: 18511651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal interaction between itraconazole and cimetidine.
    Karyekar CS; Eddington ND; Briglia A; Gubbins PO; Dowling TC
    J Clin Pharmacol; 2004 Aug; 44(8):919-27. PubMed ID: 15286096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic model of topotecan clearance from plasma and cerebrospinal fluid.
    Sung C; Blaney SM; Cole DE; Balis FM; Dedrick RL
    Cancer Res; 1994 Oct; 54(19):5118-22. PubMed ID: 7923128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Altered intravenous pharmacokinetics of topotecan in rats with acute renal failure (ARF) induced by uranyl nitrate: do adenosine A1 antagonists (selective/non-selective) normalize the altered topotecan kinetics in ARF?
    Mustafa S; Venkatesh P; Pasha K; Mullangi R; Srinivas NR
    Xenobiotica; 2006 Dec; 36(12):1239-58. PubMed ID: 17162470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inter- and intrapatient variability in oral topotecan pharmacokinetics: implications for body-surface area dosage regimens.
    Loos WJ; Gelderblom H; Sparreboom A; Verweij J; de Jonge MJ
    Clin Cancer Res; 2000 Jul; 6(7):2685-9. PubMed ID: 10914710
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topotecan lacks third space sequestration.
    Gelderblom H; Loos WJ; Verweij J; de Jonge MJ; Sparreboom A
    Clin Cancer Res; 2000 Apr; 6(4):1288-92. PubMed ID: 10778953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NTP Toxicology and Carcinogenesis Studies of Dimethyl Methylphosphonate (CAS No. 756-79-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1987 Nov; 323():1-172. PubMed ID: 12748730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited sampling model for area under the concentration time curve of total topotecan.
    Minami H; Beijnen JH; Verweij J; Ratain MJ
    Clin Cancer Res; 1996 Jan; 2(1):43-6. PubMed ID: 9816088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.